Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.36 |
| ▸ | DOT1L | Q8TEK3 | 5/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19412426 | 0.85 | POLRMT (0.34) | POLRMTDOT1L | |
| SCHEMBL25401925 | 0.84 | POLRMT (0.37) | POLRMTDOT1LACVRL1 | |
| SCHEMBL17131349 | 0.84 | POLRMT (0.35) | POLRMTDOT1L | |
| SCHEMBL19412761 | 0.83 | POLRMT (0.38) | POLRMTDOT1LMAP4K4ACVRL1 | |
| SCHEMBL17131348 | 0.82 | POLRMT (0.34) | POLRMTDOT1L | |
| SCHEMBL17131357 | 0.82 | STING1 (0.30) | — | |
| SCHEMBL17106816 | 0.81 | POLRMT (0.34) | POLRMTDOT1L | |
| SCHEMBL17106802 | 0.81 | POLRMT (0.34) | POLRMTDOT1L | |
| SCHEMBL26270281 | 0.81 | POLRMT (0.38) | POLRMTDOT1LMAP4K4ACVRL1 | |
| SCHEMBL17106845 | 0.78 | POLRMT (0.37) | POLRMTDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | POLRMT 7/4885DOT1L 799/4885MAP4K4 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.